Quick Answer
Atea Pharmaceuticals, Inc. reported Cash and Equivalents of $95.71 million for fiscal year 2025.
Atea Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $95.71M | +47.9% |
| 2024 | $64.70M | -55.0% |
| 2023 | $143.82M | -23.7% |
| 2022 | $188.46M | -75.3% |
| 2021 | $764.38M | -10.1% |
| 2020 | $850.12M | +3824.6% |
| 2019 | $21.66M | -37.2% |
| 2018 | $34.49M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $77.34M | -21.4% | -11.8% |
| June 30, 2025 | $87.72M | -64.0% | -26.5% |
| March 31, 2025 | $119.39M | -25.8% | +84.5% |
| December 31, 2024 | $64.70M | -55.0% | -34.3% |
| September 30, 2024 | $98.46M | -28.6% | -59.5% |
| June 30, 2024 | $243.39M | +13.9% | +51.3% |
| March 31, 2024 | $160.91M | -12.2% | +11.9% |
| December 31, 2023 | $143.82M | -23.7% | +4.3% |
- Atea Pharmaceuticals, Inc. showed an increase of +47.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, Atea Pharmaceuticals, Inc.’s cash and equivalents has grown by 177.5% (from $34.49 million to $95.71 million).
- The most recent figure is from Atea Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: